GeneDx (WGS)
Market Price (4/15/2026): $67.2 | Market Cap: $2.0 BilSector: Health Care | Industry: Life Sciences Tools & Services
GeneDx (WGS)
Market Price (4/15/2026): $67.2Market Cap: $2.0 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 40% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.1% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 58x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% Short seller reportGrizzly Reports report on 0/25/2025. Key risksWGS key risks include [1] legal and financial fallout from investigations into alleged fraudulent billing practices, Show more. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 40% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -41% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 14% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -13 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3.1% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 58x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0% |
| Short seller reportGrizzly Reports report on 0/25/2025. |
| Key risksWGS key risks include [1] legal and financial fallout from investigations into alleged fraudulent billing practices, Show more. |
Qualitative Assessment
AI Analysis | Feedback
GeneDx (WGS) stock has lost about 50% since 12/31/2025 because of the following key factors:
1. Q4 2025 Revenue Miss and GAAP Net Loss.
GeneDx reported fourth-quarter 2025 revenue of $121.0 million, which slightly missed the analyst consensus estimate of approximately $121.6 million. Despite beating earnings per share (EPS) estimates with $0.14 per share against an estimated $0.11, the company posted a GAAP net loss of $17.7 million for the quarter. This mixed financial performance, particularly the revenue shortfall and the GAAP loss, contributed to a negative market reaction, with the stock experiencing a significant decline in subsequent trading sessions after an initial brief gain.
2. Substantial Analyst Price Target Reductions.
Following the Q4 2025 financial results, multiple prominent analysts significantly reduced their price targets for GeneDx. For example, Guggenheim maintained its "Buy" rating but lowered its price target by 41.18%, from $170 to $100, on March 30, 2026. Similarly, BTIG adjusted its price target from $200 to $170, and Piper Sandler reduced its target from $160 to $130, both on February 24, 2026. These downward revisions from key financial institutions signaled a reassessment of the company's valuation, contributing to the stock's decline.
Show more
1. Q4 2025 Revenue Miss and GAAP Net Loss.
GeneDx reported fourth-quarter 2025 revenue of $121.0 million, which slightly missed the analyst consensus estimate of approximately $121.6 million. Despite beating earnings per share (EPS) estimates with $0.14 per share against an estimated $0.11, the company posted a GAAP net loss of $17.7 million for the quarter. This mixed financial performance, particularly the revenue shortfall and the GAAP loss, contributed to a negative market reaction, with the stock experiencing a significant decline in subsequent trading sessions after an initial brief gain.
2. Substantial Analyst Price Target Reductions.
Following the Q4 2025 financial results, multiple prominent analysts significantly reduced their price targets for GeneDx. For example, Guggenheim maintained its "Buy" rating but lowered its price target by 41.18%, from $170 to $100, on March 30, 2026. Similarly, BTIG adjusted its price target from $200 to $170, and Piper Sandler reduced its target from $160 to $130, both on February 24, 2026. These downward revisions from key financial institutions signaled a reassessment of the company's valuation, contributing to the stock's decline.
Show more
Stock Movement Drivers
Fundamental Drivers
The -48.6% change in WGS stock from 12/31/2025 to 4/14/2026 was primarily driven by a -51.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 130.06 | 66.86 | -48.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 402 | 428 | 6.3% |
| P/S Multiple | 9.3 | 4.5 | -51.2% |
| Shares Outstanding (Mil) | 29 | 29 | -0.9% |
| Cumulative Contribution | -48.6% |
Market Drivers
12/31/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| WGS | -48.6% | |
| Market (SPY) | -5.4% | 22.6% |
| Sector (XLV) | -3.9% | 22.9% |
Fundamental Drivers
The -37.9% change in WGS stock from 9/30/2025 to 4/14/2026 was primarily driven by a -46.5% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 107.74 | 66.86 | -37.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 362 | 428 | 18.0% |
| P/S Multiple | 8.5 | 4.5 | -46.5% |
| Shares Outstanding (Mil) | 29 | 29 | -1.6% |
| Cumulative Contribution | -37.9% |
Market Drivers
9/30/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| WGS | -37.9% | |
| Market (SPY) | -2.9% | 32.1% |
| Sector (XLV) | 7.4% | 27.3% |
Fundamental Drivers
The -24.5% change in WGS stock from 3/31/2025 to 4/14/2026 was primarily driven by a -43.6% change in the company's P/S Multiple.| (LTM values as of) | 3312025 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 88.56 | 66.86 | -24.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 305 | 428 | 40.0% |
| P/S Multiple | 8.1 | 4.5 | -43.6% |
| Shares Outstanding (Mil) | 28 | 29 | -4.4% |
| Cumulative Contribution | -24.5% |
Market Drivers
3/31/2025 to 4/14/2026| Return | Correlation | |
|---|---|---|
| WGS | -24.5% | |
| Market (SPY) | 16.3% | 32.6% |
| Sector (XLV) | 3.3% | 25.1% |
Fundamental Drivers
The 455.1% change in WGS stock from 3/31/2023 to 4/14/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4142026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.04 | 66.86 | 455.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 428 | 0.0% |
| P/S Multiple | � | 4.5 | 0.0% |
| Shares Outstanding (Mil) | 7 | 29 | -74.9% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/14/2026| Return | Correlation | |
|---|---|---|
| WGS | 455.1% | |
| Market (SPY) | 63.3% | 19.5% |
| Sector (XLV) | 20.4% | 13.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| WGS Return | -60% | -94% | -68% | 2695% | 69% | -54% | -84% |
| Peers Return | 38% | -41% | 2% | 26% | 23% | -11% | 14% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 81% |
Monthly Win Rates [3] | |||||||
| WGS Win Rate | 33% | 25% | 33% | 75% | 58% | 0% | |
| Peers Win Rate | 67% | 35% | 42% | 52% | 55% | 35% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| WGS Max Drawdown | -60% | -95% | -86% | -4% | -27% | -56% | |
| Peers Max Drawdown | -5% | -52% | -24% | -20% | -18% | -16% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ILMN, NTRA, DGX, LH, FLGT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/14/2026 (YTD)
How Low Can It Go
| Event | WGS | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -99.9% | -25.4% |
| % Gain to Breakeven | 68587.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to ILMN, NTRA, DGX, LH, FLGT
In The Past
GeneDx's stock fell -99.9% during the 2022 Inflation Shock from a high on 2/12/2021. A -99.9% loss requires a 68587.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GeneDx (WGS)
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
AI Analysis | Feedback
Here are 1-3 brief analogies for GeneDx (WGS):
- 23andMe for medical diagnoses and drug development.
- Palantir for genomic health data.
- Foundation Medicine for broader genetic testing.
AI Analysis | Feedback
- Centrellis Platform: An AI-driven health intelligence platform providing insights and support for biopharma in drug discovery and development.
- Sema4 Signal: A platform designed to enable and advance precision oncology care across prevention, treatment, and remission.
- Genetic Diagnostic Testing: Offers a range of tests including carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing.
- COVID-19 Testing Solutions: Provides testing services for the COVID-19 virus.
AI Analysis | Feedback
GeneDx (WGS) primarily sells its services and platform to other companies and institutions. Based on the provided background, the major customer categories include:- Biopharmaceutical Companies: These companies are customers for GeneDx's AI-driven health intelligence platform (Centrellis), which delivers comprehensive insights to accelerate drug discovery, development, and commercialization. They also utilize GeneDx for analytics, pre-clinical and clinical trial support, and advanced sequencing services. Specific customer names are not provided in the background.
- Healthcare Providers and Systems: This category includes hospitals, clinics, and oncology centers. These customers utilize GeneDx's Sema4 Signal for precision oncology care and rely on the company for various diagnostic testing services, such as carrier screening, noninvasive prenatal testing, newborn screening, hereditary cancer testing, and COVID-19 testing solutions. Specific customer names are not provided in the background.
AI Analysis | Feedback
- Illumina, Inc. (ILMN)
- Thermo Fisher Scientific Inc. (TMO)
- Pacific Biosciences of California, Inc. (PACB)
- Amazon Web Services, Inc. (Parent company: Amazon.com, Inc., symbol: AMZN)
AI Analysis | Feedback
Katherine Stueland Chief Executive Officer
Katherine Stueland joined GeneDx as President and Chief Executive Officer in June 2021. She is credited with leading the company to profitability from a financially challenged state within three years. With over two decades of experience, she has scaled precision medicine companies, built robust teams, and supported the FDA approval of several rare disease therapeutics, including the first HIV protease inhibitor and the first cancer immunotherapy. Prior to GeneDx, she served as Chief Commercial Officer at Invitae Corporation, where she was instrumental in the company's growth from a private entity to a public one with a market capitalization exceeding $6 billion. Her career also includes roles at Dendreon Corporation and TAP Pharmaceuticals. Stueland has been recognized on the 2026 TIME100 Health list and the 2025 CNBC Changemakers list.
Kevin Feeley Chief Financial Officer
Kevin Feeley serves as the Chief Financial Officer at GeneDx, overseeing financial strategy, management, and planning. He brings over 20 years of finance and accounting leadership experience, primarily within the healthcare, pharmaceutical, and diagnostics sectors. Before his role at GeneDx, Feeley spent six years as the Chief Financial Officer for OPKO Health's diagnostics division, which encompassed BioReference Laboratories, Inc. and GeneDx. During the COVID-19 pandemic, he led the operational design and execution of BioReference's sports diagnostic program for major U.S. sports leagues. His prior experience also includes serving as U.S. Controller at Reckitt Benckiser and leading SEC reporting at Bausch Health Companies. Feeley is a Certified Public Accountant and previously worked for twelve years in the audit practice of KPMG LLP.
Bryan Dechairo Chief Operating Officer
Bryan Dechairo was appointed Chief Operating Officer of GeneDx in January 2025. He brings over 30 years of experience in both exploratory and commercial diagnostic businesses. Before joining GeneDx, Dechairo was the President and CEO of Sherlock Biosciences, where he transitioned the company from a research-stage startup to a commercial operation. His extensive background includes executive leadership positions at prominent diagnostic and pharmaceutical companies such as Pfizer, Myriad Genetics, Assurex, and Medco Health. Dechairo holds a PhD in Human Genetics.
Melanie Duquette Chief Growth Officer
Melanie Duquette joined GeneDx as Chief Growth Officer in September 2023. She is responsible for the company's overall growth strategy and leads the sales, market access, clinician marketing, and client services functions. Duquette has nearly 20 years of experience in the genomic industry. She previously spent a decade at Invitae, where she focused on driving commercial growth strategies to expand the utilization of genetic testing. At Invitae, she served as Head of US Sales, overseeing a large sales and business development organization, and also spearheaded the company's expansion into over 100 international markets.
Heidi Chen Chief Legal Officer
Heidi Chen serves as the Chief Legal Officer at GeneDx.
AI Analysis | Feedback
GeneDx (symbol: WGS) faces several key risks to its business operations, stemming from its position as a health information company utilizing an AI-driven health intelligence platform and offering extensive genetic testing services. The key risks include:- Regulatory and Reimbursement Challenges: As a provider of genetic testing services, including carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing, GeneDx is significantly exposed to the evolving and complex landscape of regulatory approvals and insurance reimbursement policies. The adoption of genomic testing by clinicians and coverage by insurance payers remain critical factors influencing the company's revenue and profitability. Obtaining and maintaining favorable reimbursement rates and navigating diverse state and federal regulations, such as those from the FDA, are continuous challenges that directly impact the market acceptance and financial viability of its diagnostic offerings.
- Data Privacy, Cybersecurity, and Algorithmic Bias Risks: Operating an AI-driven health intelligence platform like Centrellis and handling vast amounts of sensitive genomic and clinical data subjects GeneDx to substantial data privacy and cybersecurity risks. The potential for unauthorized access, data breaches, and violations of stringent privacy laws and regulations (e.g., HIPAA, GDPR) is a significant concern. Furthermore, AI systems, if trained on biased or incomplete datasets, can perpetuate or amplify disparities in care, leading to inaccurate diagnoses or treatments, which can harm patients, erode trust, and result in severe legal and financial consequences. The re-identification risk of even de-identified genomic data adds another layer of complexity to data security.
- Intense Competition and Rapid Technological Obsolescence: The field of genetic testing, precision oncology, and AI-driven health intelligence platforms is highly dynamic and competitive. GeneDx operates in an environment where technological advancements are rapid, and new, more cost-effective, or superior solutions from competitors could quickly emerge. The company's ability to maintain its competitive edge and market share depends on continuous innovation and staying ahead of numerous established and emerging competitors in the healthcare sector.
AI Analysis | Feedback
- The increasing commoditization and intensified price competition in the established clinical genetic testing markets (e.g., carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing). As more providers enter these spaces and sequencing costs decline, larger diagnostic laboratories with greater scale and broader payer coverage can drive down prices, eroding profit margins and market share for specialized providers like GeneDx.
- The expansion of large technology companies and established biopharmaceutical firms into the AI-driven health intelligence platform sector. These entities possess vast computational resources, extensive data sets, and significant investment capital, enabling them to develop or acquire sophisticated platforms that could directly compete with GeneDx's Centrellis platform for biopharma clients in drug discovery, development, and commercialization.
AI Analysis | Feedback
GeneDx (WGS) operates in several addressable markets related to genetic testing and genomic insights. The company itself has provided estimates for its core market opportunities.
- For its immediate market focused on rare diseases and pediatrics, GeneDx estimated an addressable market of $3 billion in the U.S. in Q2-2024. By expanding into screenings for both newborns and adults, this market was identified as an additional $26 billion. Later, the company's management estimated a total addressable market of $45 billion in the U.S. for its core genomic testing services.
- The global market for Genomic Newborn Screening (gNBS) was valued at USD 1,153.1 million in 2025 and is expected to reach USD 1,877.2 million by 2034.
- The global Non-invasive Prenatal Testing (NIPT) market was estimated at USD 6.75 billion in 2024 and is projected to reach approximately USD 20.59 billion by 2034. North America held the largest share of the NIPT market.
- The global Carrier Screening market size was estimated at USD 1.64 billion in 2025 and is projected to reach USD 4.05 billion by 2033. North America dominated the global carrier screening market.
- For its AI-driven health intelligence platform for biopharma, the global Artificial Intelligence (AI) in Biopharmaceutical market size was calculated at USD 1.99 billion in 2025 and is predicted to increase to approximately USD 29.78 billion by 2035. North America contributed significantly to this market's revenue.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for GeneDx (WGS) over the next 2-3 years: * Increased Volume and Adoption of Exome and Genome Testing: GeneDx anticipates continued strong growth in its core exome and genome testing services. The company expects full-year 2026 exome and genome growth to be between 33% and 35% in both revenue and test volumes, building on significant growth in previous years. This sustained expansion of its primary offerings is a fundamental driver of revenue. * Expansion into New and Underpenetrated Markets: GeneDx is strategically expanding its reach into new clinical settings and patient populations. Key areas of focus include general pediatrics, neonatal intensive care units (NICU), and prenatal care. This market penetration is expected to contribute to a significant portion of future growth. * Introduction of New Products and Services: The company is launching new offerings to diversify and enhance its portfolio. An example is GenomeDx Prenatal, a whole genome sequencing test for fetal anomalies, which became available to clinicians in February 2026. Additionally, GeneDx unveiled Multiscore, an advanced AI-powered decision support tool designed to improve diagnostic efficiency and clinical insights. New products are expected to contribute to revenue growth. * Leveraging the GeneDx Infinity Data Platform and AI: GeneDx utilizes its GeneDx Infinity, described as the world's largest rare disease genomic dataset, and its AI-driven platform to enhance diagnostic accuracy, streamline workflows, and generate comprehensive insights. This technological advantage and data leadership are expected to drive sustained and profitable growth by improving the value and effectiveness of its services. * Expansion of Commercial Footprint: To support its growth initiatives, GeneDx plans to significantly increase its commercial presence. Management intends to nearly triple its commercial footprint in 2026 by adding approximately 100 sales representatives. This investment in sales and marketing is aimed at accelerating market capture and driving higher testing volumes.AI Analysis | Feedback
Share Issuance
- Sema4 went public via a SPAC merger in July 2021, raising approximately $500 million in cash proceeds.
- In the second quarter of 2022, Sema4 completed a $200 million private placement of Class A shares to institutional investors, including Pfizer, in conjunction with the GeneDx acquisition.
- GeneDx raised $31.9 million in the fourth quarter of 2024 and an additional $21.1 million in 2025 through "at-the-market" offerings.
Inbound Investments
- The SPAC merger in 2021 included a $350 million private investment in public equity (PIPE) from various investors, including Casdin Capital, Corvex Management, Fidelity, Morgan Stanley, SoftBank, T Rowe, and Viking.
- A $200 million private placement from institutional investors, notably Pfizer, was secured in the second quarter of 2022 alongside the GeneDx acquisition.
- Goldman Sachs Group Inc. acquired 1,337,105 shares of GeneDx (WGS) for approximately $56.7 million in September 2024.
Outbound Investments
- Sema4 acquired GeneDx from OPKO Health in the second quarter of 2022 for an upfront payment of $150 million in cash plus 80 million shares of Sema4, with potential additional milestone payments, valuing the total consideration between approximately $322 million and $623 million.
- GeneDx completed the acquisition of Fabric Genomics in May 2025 for up to $33 million in cash at closing, with total potential consideration of up to $51 million based on milestone achievements.
- Sema4 (prior to rebranding as GeneDx) exited its somatic tumor testing business and discontinued COVID-19 testing services by March 2022, and also shut down its reproductive health unit to focus on GeneDx's genetic testing operations.
Capital Expenditures
- In 2021, Sema4 made investments in systems, increased headcount, and covered higher logistical and supply costs to support volume growth and improve cost efficiencies.
- Research and development expenses for Sema4 increased by $1.5 million (62%) to $4.0 million in the first quarter of 2022, primarily due to higher personnel costs in laboratory automation and robotics, bioinformatics, and data R&D.
- GeneDx is investing in its commercial team, planning to nearly triple its sales representatives from approximately 60 to 160 in 2025 to accelerate growth, and launched significant enhancements to its whole genome sequencing (WGS) products in the fourth quarter of 2024.
Latest Trefis Analyses
Trade Ideas
Select ideas related to WGS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 162.24 |
| Mkt Cap | 20.4 |
| Rev LTM | 3,325 |
| Op Inc LTM | 401 |
| FCF LTM | 504 |
| FCF 3Y Avg | 297 |
| CFO LTM | 647 |
| CFO 3Y Avg | 416 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 12.8% |
| Rev Chg 3Y Avg | 3.8% |
| Rev Chg Q | 8.2% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 3.9% |
| Op Mgn 3Y Avg | -6.8% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 10.5% |
| CFO/Rev 3Y Avg | 4.9% |
| FCF/Rev LTM | 6.0% |
| FCF/Rev 3Y Avg | 0.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 20.4 |
| P/S | 3.2 |
| P/EBIT | 3.0 |
| P/E | 6.5 |
| P/CFO | 15.9 |
| Total Yield | 1.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.0% |
| D/E | 0.1 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.2% |
| 3M Rtn | -10.6% |
| 6M Rtn | 1.1% |
| 12M Rtn | 18.4% |
| 3Y Rtn | 32.4% |
| 1M Excs Rtn | 0.1% |
| 3M Excs Rtn | -9.5% |
| 6M Excs Rtn | -4.5% |
| 12M Excs Rtn | -9.8% |
| 3Y Excs Rtn | -38.3% |
Price Behavior
Price Behavior
| Market Price | $66.86 | |
| Market Cap ($ Bil) | 1.9 | |
| First Trading Date | 11/04/2020 | |
| Distance from 52W High | -60.1% | |
| 50 Days | 200 Days | |
| DMA Price | $77.74 | $110.40 |
| DMA Trend | indeterminate | down |
| Distance from DMA | -14.0% | -39.4% |
| 3M | 1YR | |
| Volatility | 77.2% | 81.0% |
| Downside Capture | 1.09 | 0.77 |
| Upside Capture | -44.42 | 60.52 |
| Correlation (SPY) | 23.5% | 30.1% |
WGS Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.25 | 1.07 | 1.29 | 1.59 | 1.39 | 1.41 |
| Up Beta | 8.14 | 1.11 | 1.75 | 2.73 | 1.86 | 1.48 |
| Down Beta | 2.47 | 1.24 | 1.70 | 1.25 | 1.09 | 0.89 |
| Up Capture | 17% | -58% | -87% | 60% | 59% | 748% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 10 | 18 | 28 | 62 | 122 | 351 |
| Down Capture | 234% | 205% | 225% | 178% | 120% | 108% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 12 | 24 | 35 | 64 | 129 | 395 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGS | |
|---|---|---|---|---|
| WGS | -24.5% | 80.9% | 0.05 | - |
| Sector ETF (XLV) | 11.9% | 16.0% | 0.52 | 22.2% |
| Equity (SPY) | 24.2% | 12.9% | 1.49 | 30.9% |
| Gold (GLD) | 53.4% | 27.6% | 1.55 | 0.2% |
| Commodities (DBC) | 26.8% | 16.2% | 1.47 | -9.6% |
| Real Estate (VNQ) | 18.7% | 13.8% | 1.00 | 19.3% |
| Bitcoin (BTCUSD) | -6.8% | 42.9% | -0.05 | 9.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGS | |
|---|---|---|---|---|
| WGS | -36.5% | 106.6% | 0.06 | - |
| Sector ETF (XLV) | 6.6% | 14.6% | 0.27 | 20.1% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 29.4% |
| Gold (GLD) | 22.5% | 17.8% | 1.03 | 4.7% |
| Commodities (DBC) | 11.7% | 18.8% | 0.51 | 5.3% |
| Real Estate (VNQ) | 3.9% | 18.8% | 0.11 | 22.6% |
| Bitcoin (BTCUSD) | 5.8% | 56.5% | 0.32 | 16.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGS | |
|---|---|---|---|---|
| WGS | -17.1% | 106.0% | 0.15 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 20.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 29.3% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 5.2% |
| Commodities (DBC) | 8.8% | 17.6% | 0.42 | 5.4% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.23 | 22.4% |
| Bitcoin (BTCUSD) | 67.7% | 66.9% | 1.07 | 14.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 1/12/2026 | -7.9% | -16.4% | -23.3% |
| 10/28/2025 | 5.2% | 5.8% | 28.2% |
| 7/29/2025 | 8.1% | 27.6% | 48.7% |
| 4/30/2025 | -42.8% | -45.9% | -40.2% |
| 1/13/2025 | -4.9% | -22.3% | -24.1% |
| 10/29/2024 | 49.9% | 34.1% | 43.6% |
| 7/30/2024 | 8.6% | -4.3% | 5.2% |
| 4/29/2024 | 55.2% | 77.5% | 92.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 7 | 7 |
| # Negative | 11 | 11 | 11 |
| Median Positive | 40.4% | 33.1% | 43.6% |
| Median Negative | -12.1% | -22.9% | -33.0% |
| Max Positive | 55.2% | 92.1% | 92.3% |
| Max Negative | -42.8% | -52.5% | -71.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/23/2026 | 10-K |
| 09/30/2025 | 10/28/2025 | 10-Q |
| 06/30/2025 | 07/29/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 10/29/2024 | 10-Q |
| 06/30/2024 | 07/30/2024 | 10-Q |
| 03/31/2024 | 04/29/2024 | 10-Q |
| 12/31/2023 | 02/23/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/23/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 540.00 Mil | 547.50 Mil | 555.00 Mil | 28.4% | Raised | Guidance: 426.50 Mil for 2025 | |
| 2026 Growth in exome and genome revenue | 33.0% | 34.0% | 35.0% | -37.0% | -20.0% | Lowered | Guidance: 54.0% for 2025 |
| 2026 Growth in exome and genome volume | 33.0% | 34.0% | 35.0% | 13.3% | 4.0% | Raised | Guidance: 30.0% for 2025 |
| 2026 Adjusted gross margin | 70.0% | -0.7% | -0.5% | Lowered | Guidance: 70.5% for 2025 | ||
| 2026 Adjusted net income | |||||||
Prior: Q3 2025 Earnings Reported 10/28/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 425.00 Mil | 426.50 Mil | 428.00 Mil | 4.7% | Raised | Guidance: 407.50 Mil for 2025 | |
| 2025 Growth in exome and genome revenue | 53.0% | 54.0% | 55.0% | 8.0% | 4.0% | Raised | Guidance: 50.0% for 2025 |
| 2025 Growth in exome and genome volume | 30.0% | 0 | Affirmed | Guidance: 30.0% for 2025 | |||
| 2025 Adjusted gross margin | 70.0% | 70.5% | 71.0% | 1.4% | 1.0% | Raised | Guidance: 69.5% for 2025 |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Feeley, Kevin | CHIEF FINANCIAL OFFICER | Direct | Sell | 12182025 | 143.87 | 3,855 | 554,616 | 1,256,123 | Form |
| 2 | Stueland, Katherine | CHIEF EXECUTIVE OFFICER | Direct | Sell | 12182025 | 143.89 | 10,857 | 1,562,185 | 2,048,525 | Form |
| 3 | Feeley, Kevin | CHIEF FINANCIAL OFFICER | Direct | Sell | 12112025 | 159.28 | 1,266 | 201,648 | 858,360 | Form |
| 4 | Stueland, Katherine | CHIEF EXECUTIVE OFFICER | Direct | Sell | 12112025 | 159.28 | 3,639 | 579,620 | 1,010,472 | Form |
| 5 | Feeley, Kevin | CHIEF FINANCIAL OFFICER | Direct | Sell | 12032025 | 162.54 | 377 | 61,276 | 681,513 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.